Astellas

Through our efforts in Primary Focus Blindness and Regeneration, we are committed to developing transformative therapies to restore sight and free patients from the fear of deteriorating vision.

Recognizing the significant challenges of delivering entirely new modalities, we are pursuing a long-term cell and gene therapy strategy to pioneer new treatments for patients. We are establishing a robust and differentiated regenerative medicine platform combining our deep understanding of the biology of eye diseases with cutting-edge cell and gene modalities. With a pipeline of several regenerative medicine programs, we have the potential to transform the treatment of multiple eye diseases.

Taking a unique approach to restoring and preserving sight

Sight connects people to the world around them and to the people and experiences they love. Vision loss, caused by diseases of the eye, affects over 160 million people globally and can have a devasting impact on quality of life. United by a shared sense of urgency, passion and persistence to deliver for patients in need, we are targeting the underlying causes of eye diseases. Our long-term goal is to develop innovative therapies that significantly improve people’s vision and may help to restore their access to everyday life.